Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 24, 2011

View Archived Issues

Crizotinib suppresses osteosarcoma and associated osteolytic/osteoblastic changes in vivo

Combination therapies including cediranib well tolerated in patients with gastric cancer

Parthenolide sensitizes osteosarcoma cells to radiation

Sonias tablet approved in Japan for type 2 diabetes

Febuxostat approved in Japan for gout

Longdaysin prolongs circadian rhythms in vitro and in vivo

New inhibitors of HCV NS5B identified at Vivalis

New inhibitors of heat shock protein HSP 90 presented

Mologen provides pipeline update

Chelsea Therapeutics reports data on Northera in neurogenic orthostatic hypotension

New inhibitors of hepatocyte growth factor receptor claimed

Florbetapir-PET imaging in patients with Alzheimer's disease

CHMP adopts positive opinion for Gilenya in relapsing-remitting MS

Vidaza approved in Japan for myelodysplastic syndromes

New prostanoid DP2 receptor antagonists discovered

Auris Medical advances phase IIb trial of AM-111 for acute sensorineural hearing loss

Pradaxa approved in Japan for prevention of stroke in atrial fibrillation

Novel beta-secretase 1 inhibitors developed at AstraZeneca

RiVax receives FDA orphan drug status for prevention of ricin intoxication

CHMP adopts final negative opinion for cladribine tablets in relapsing-remitting MS

CHMP recommends approval of Jevtana combination regimen for prostate cancer

CHMP decides against approval of Fampyra to improve walking in MS

CBLB-502 demonstrates direct anticancer effect in preclinical models

Romiplate IV injection approved in Japan for chronic ITP

Purdue Pharma launches Butrans transdermal system CIII in U.S. for chronic pain

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...
News in brief
BioWorld Asia
BioWorld Asia briefs for Feb. 10, 2026